News and Updates

DoJ announced that a vendor and his distribution company were sentenced for unlawfully smuggling and selling unapproved SARMs.

The 4th Annual OPSS Summit convened over 270 military, medical, and sports leaders to discuss dietary supplement safety, performance-enhancing substances, and Service Member readiness. 

FDA has finalized guidance detailing the identity and safety information industry must include in New Dietary Ingredient (NDI) notifications before marketing products to consumers.

See the newest additions to the DoD Prohibited Dietary Supplement Ingredients List. 

FDA issues warning letters to companies selling peptides as "research chemicals" and warns consumers about the serious health consequences of using unapproved injectable peptides.

Check out the new "Questions & Answers" landing page on testosterone and related topics (including medical care and dietary supplements) on the OPSS website.

FDA is urging consumers to stop using and seek medical advice regarding certain hyaluronic acid products marketed for pain relief, as laboratory testing revealed hidden drug ingredients that pose severe health risks.

FDA issues 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products.

FDA warns consumers about illegal bodybuilding dietary supplement products, which often contain SARMs.

FDA and DoJ seize thousands of 7-hydroxymitragynine (7-OH) products.

FDA established a "green list" import alert to safeguard consumers from potentially dangerous GLP-1 active ingredients imported from overseas.

FDA continues to alert healthcare professionals and consumers about the risks of 7-hydroxymitragynine.